Cftr Trikafta denied for missing prior authorization by Aetna?

Aetna's specific coverage criteria for cftr trikafta are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Aetna Requires Prior Authorization for Trikafta

Prior authorization (PA) is Aetna's administrative requirement that clinical criteria be reviewed and approved before a specialty drug will be covered. For Trikafta, PA is nearly universal across commercial plans because of the drug's cost and its narrow genotype-based indication. A denial at the PA stage means either that the initial request was incomplete, that submitted documentation did not map to each policy criterion, or—in some cases—that the reviewing pharmacist or nurse did not have sufficient clinical context to approve.

A PA denial is not a final decision. It is the beginning of the appeal process, and PA denials for appropriately indicated CFTR modulators are frequently reversed.

## Your Federal Appeal Rights

• Internal appeal (Level 1): Must be requested within the deadline on your denial notice (often 60–180 days). Pre-service denials must receive a decision within 30 days (standard) or 72 hours (expedited). Request a peer-to-peer review: your prescriber speaks directly to Aetna's reviewing physician. This single step resolves a large proportion of PA denials.
• External review (ACA §2719): Available after a final internal denial. An independent external reviewer evaluates the case against objective clinical standards. The window is approximately 4 months from the final denial.
• ERISA §503 (self-funded plans): Guarantees access to all criteria and documents used in the denial.
• Expedited review: Available when waiting endangers health.

## Documentation to Gather

1. Complete PA resubmission package: Prescriber's letter of medical necessity, genetic mutation report, current pulmonary function data, clinical notes documenting CF diagnosis and disease severity, and prior therapy history. 2. Aetna's current PA criteria: Download the published CFTR modulator clinical policy. Confirm you are addressing the operative version (check the effective date). 3. Peer-to-peer request: Submit this request immediately. Aetna is required to arrange a clinician-to-clinician call. Prescribers should prepare to walk through each PA criterion with specific chart references. 4. Specialty pharmacy documentation: Confirm the medication is being dispensed through an Aetna-contracted specialty pharmacy, as PA approvals are often pharmacy-channel-specific.

## Criteria-Mapping Structure

For the internal appeal letter, build a structured table:

| Aetna PA Criterion (verbatim from policy) | Submitted Documentation | |---|---| | Eligible CF genotype confirmed | Genetic report dated __ | | Current pulmonary assessment | Spirometry report dated __ | | Prescriber is appropriate specialty | CV / treating MD credentials | | Prior therapies reviewed | Treatment history with dates |

Request the peer-to-peer call before submitting a written appeal when possible—it is faster and often more persuasive. If the peer-to-peer fails, the written appeal preserves the record for external review.